Beryl Drugs Limited disclosed on August 19, 2026, that its promoter, Sudhir Sethi, acquired 4809 equity shares in the company. The acquisition took place on August 18, 2026, through market transactions.

The purchase increased Sethi’s total holding to 518,928 shares, representing a 10.24% stake in the company’s total voting capital. Prior to this transaction, he held 514,119 shares, constituting 10.14% of the equity.

Acquisition Details

The company filed the disclosure with the stock exchanges under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The total equity share capital of the target company remained unchanged at 5,071,700 shares before and after the acquisition.

What the Numbers Show

The acquisition reflects a marginal increase in promoter ownership via open market purchases rather than off-market transfers or preferential allotments. With the promoter group maintaining a consolidated voting power above 10%, the move reinforces existing control structures without triggering open offer obligations under current regulations.

Beryl Drugs Limited reported a sharp turnaround in profitability for the first quarter of FY27, with net profit jumping 946% year-on-year to ₹22.08 lakh, driven by a 56% surge in total revenue from operations to ₹75.66 lakh. The Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, during its meeting held on August 11, 2026, at the company’s registered office in Indore, Madhya Pradesh.

The significant improvement in the bottom line was supported by robust top-line growth, as net sales rose to ₹72.97 lakh from ₹47.94 lakh in the corresponding period of FY26. This revenue expansion helped offset higher cost of materials consumed, which increased to ₹43.40 lakh from ₹22.09 lakh year-on-year. Despite the higher input costs, the company managed to expand its operating profit before tax to ₹26.98 lakh, compared to just ₹6.97 lakh in Q1FY26.

Financial Performance Highlights

The company’s financial statement for the quarter reflects improved operational efficiency and margin expansion. Key metrics include:

Total expenses stood at ₹72.97 lakh, comprising ₹43.40 lakh for materials consumed, ₹6.20 lakh in finance costs, and ₹18.57 lakh in other expenses. Employee benefit expenses remained stable at ₹6.31 lakh. The tax expense for the quarter was ₹4.90 lakh, resulting in the reported net profit of ₹22.08 lakh.

Auditor Review and Compliance

The unaudited financial results were subjected to a limited review by the statutory auditors, Subhash Chand Jain Anurag & Associates. The audit firm issued its review report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report confirms that nothing has come to their attention to suggest that the financial statements do not disclose the required information or contain material misstatements.

The Board also took on record the limited review report and reaffirmed that the company’s books of accounts are maintained at its registered office in Indore. Sudhir Sethi, Chairman & Director, and Sanjay Sethi, Managing Director, signed off on the resolutions.

What the Numbers Show

The dramatic 946% surge in net profit highlights a strong recovery in Beryl Drugs’ operational performance after a lean period in Q1FY26, where net profit was merely ₹2.11 lakh. The ability to grow revenue by over 56% while maintaining control over employee costs and finance charges suggests improved pricing power or volume growth in its pharmaceutical segment. With earnings per share rising tenfold to ₹0.44, shareholder value creation has accelerated significantly in the opening quarter of the fiscal year.